NCT00931138View on ClinicalTrials.gov

Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2

PHASE3CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

December 31, 1999

Study Completion Date

December 31, 2006

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

chemotherapy (Aracytine + Daunorubicin)

Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3

DRUG

chemotherapy (Aracytine + Daunorubicin)

Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3

DRUG

chemotherapy (Aracytine + Daunorubicin)

Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4

Trial Locations (16)

14033

CH, Caen

59037

CHU, Lille

59100

CH, Roubaix

59322

CH, Valenciennes

62307

CH, Lens

75012

St Antoine Hospital, Paris

75651

Hopital Pitie-Salpetriere, Paris

76038

CHU, Rouen

87042

CH, Limoges

92141

Hopital Percy, Clamart

92210

CNLCC, Saint-Cloud

94010

CHU, Créteil

94805

IGR, Villejuif

Unknown

Hopital Edouard Herriot, Lyon

Hopital Saint-Louis, Paris

CH, Versailles

All Listed Sponsors
collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

lead

Acute Leukemia French Association

OTHER